Digital Pharma: Lilly aims to be social on its Lillypad
pharmafile | September 16, 2010 | News story | Medical Communications | Digital Pharma blog, Twitter, blog, lilly
Lilly has jumped feet first into the social media scene this week, launching a corporate blog and a Twitter account.
The addition of Lilly to the ranks of blogging pharma companies is noteworthy because it means that exactly half of the ten biggest pharma companies now run a corporate blog.
The punningly titled LillyPad blog aims to cover areas like public policy, corporate responsibility initiatives, advocacy, and the work of its employees.
In an introductory post Lilly’s Greg Kueterman explained why the company had set up its blog.
“We feel passionately about a lot of issues that are important to our company and our industry, and we know there’s plenty of passion well beyond our own walls. Policy issues like health care reform have been top-of-mind with the public for a long time. And industry watchers are placing an increased premium on trends like corporate citizenship.
“These are important dialogues, and we’re happy to provide a forum and participate.”
Lilly is supporting its blog with a new LillyPad Twitter account, and the company was quickly welcomed to the Twittersphere by Roche and AstraZeneca.
Pharma company blogs
Lilly’s use of Twitter is not a ground-breaking move, but in choosing to also make the larger investment required to run a blog the company is a taking a less well-travelled path within pharma.
The number of pharma company blogs has slowly risen since 2007, when Johnson & Johnson launched the industry’s first one with JnJ BTW.
Since then GlaxoSmithKline, Pfizer and – most recently – AstraZeneca have all joined the blogosphere.
Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.
Related Content
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …
University of Glasgow and Lilly sign £4.6m immunological disease partnership
The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, …
